Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Gamba-Vitalo

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Nucleic Acid Therapeutics|January 8, 2013
Oligo safety working group exaggerated pharmacology subcommittee consensus documentDoug Kornbrust, Joy Cavagnaro, Arthur Levin, et al.
Silence|July 10, 2010
A status report on RNAi therapeuticsAkshay K Vaishnaw, Jared Gollob, Christina Gamba-Vitalo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 5, 2009
Development of lipidoid-siRNA formulations for systemic delivery to the liverAkin Akinc, Michael Goldberg, June Qin, et al.
The New England Journal of Medicine|August 30, 2013
Safety and efficacy of RNAi therapy for transthyretin amyloidosisTeresa Coelho, David Adams, Ana Silva, et al.
Cancer Discovery|January 30, 2013
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvementJosep Tabernero, Geoffrey I Shapiro, Patricia M LoRusso, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 13, 2008
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesMaria Frank-Kamenetsky, Aldo Grefhorst, Norma N Anderson, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Nucleic Acid Therapeutics|January 8, 2013
Oligo safety working group exaggerated pharmacology subcommittee consensus documentDoug Kornbrust, Joy Cavagnaro, Arthur Levin, et al.
Silence|July 10, 2010
A status report on RNAi therapeuticsAkshay K Vaishnaw, Jared Gollob, Christina Gamba-Vitalo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 5, 2009
Development of lipidoid-siRNA formulations for systemic delivery to the liverAkin Akinc, Michael Goldberg, June Qin, et al.
The New England Journal of Medicine|August 30, 2013
Safety and efficacy of RNAi therapy for transthyretin amyloidosisTeresa Coelho, David Adams, Ana Silva, et al.
Cancer Discovery|January 30, 2013
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvementJosep Tabernero, Geoffrey I Shapiro, Patricia M LoRusso, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 13, 2008
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesMaria Frank-Kamenetsky, Aldo Grefhorst, Norma N Anderson, et al.
Pageof 1